MCID: HYP066
MIFTS: 61

Hyperglycemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperglycemia

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 12 74 29 54 6 42 44 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4195
MeSH 44 D006943
NCIt 50 C26797
SNOMED-CT 67 144187006
ICD10 32 R73.9
UMLS 71 C0020456

Summaries for Hyperglycemia

MedlinePlus : 42 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to permanent neonatal diabetes mellitus and maturity-onset diabetes of the young, type 2, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Sirolimus and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include endothelial, kidney and pancreas, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 74 Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma.... more...

Related Diseases for Hyperglycemia

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 906)
# Related Disease Score Top Affiliating Genes
1 permanent neonatal diabetes mellitus 32.4 PDX1 KCNJ11 INS HNF1A GCK GCG
2 maturity-onset diabetes of the young, type 2 32.4 PDX1 KCNJ11 INS HNF1A GCK ABCC8
3 transient neonatal diabetes mellitus 32.3 PDX1 KCNJ11 INS GCK ABCC8
4 diabetes mellitus, permanent neonatal, 1 32.3 PDX1 KCNJ11 INS GCK ABCC8
5 diabetes mellitus, ketosis-prone 32.3 SLC5A2 KCNJ11 INS GCG DPP4 ALB
6 renal glucosuria 32.2 SLC5A2 INS HNF1A
7 neonatal diabetes 32.1 PDX1 KCNJ11 INS GCK ABCC8
8 type 1 diabetes mellitus 20 32.0 INS IGF1 HNF1A
9 donohue syndrome 32.0 IRS1 INSR INS IGF1 GCK
10 hypoglycemia 32.0 SST KCNJ11 INSR INS IGF1 IAPP
11 hyperinsulinism 32.0 SST PPARG LEP KCNJ11 IRS1 INSR
12 type 1 diabetes mellitus 32.0 SST PDX1 LEP INSR INS IGF1
13 microvascular complications of diabetes 5 31.7 INS IGF1 ALB AKR1B1
14 pancreatic cholera 31.7 SST GCG
15 lipid metabolism disorder 31.7 PPARG LEP IRS1 INSR INS ADIPOQ
16 type 2 diabetes mellitus 31.5 SST SLC5A2 PPARG PDX1 LEP KCNJ11
17 gestational diabetes 31.5 PPARG LEP KCNJ11 IRS1 INSR INS
18 microvascular complications of diabetes 3 31.4 MALAT1 INS ALB AKR1B1
19 atherosclerosis susceptibility 31.3 PPARG LEP INS ALB ADIPOQ
20 myocardial infarction 31.3 PPARG PDX1 LEP INS IGF1 DPP4
21 glucose intolerance 31.3 SST PPARG LEP KCNJ11 IRS1 INSR
22 vascular disease 31.3 PPARG LEP INS IGF1 ALB ADIPOQ
23 diabetic neuropathy 31.2 LEP INS AKR1B1
24 non-alcoholic fatty liver disease 31.2 PPARG LEP IRS1 INSR INS IGF1
25 peripheral nervous system disease 31.1 SST PPARG INS IGF1 GCG ALB
26 end stage renal disease 31.1 LEP INS ALB ADIPOQ
27 retinal vascular disease 31.0 INS IGF1 ALB AKR1B1
28 acromegaly 31.0 SST LEP INS IGF1 ADIPOQ
29 autonomic neuropathy 31.0 INS GCG ALB AKR1B1
30 chronic kidney disease 30.9 SLC5A2 PPARG LEP INS IGF1 GCG
31 body mass index quantitative trait locus 11 30.9 PPARG LEP KCNJ11 IRS1 INSR INS
32 insulinoma 30.9 SST PDX1 INS IAPP HNF1A GCK
33 acute insulin response 30.9 KCNJ11 INS GCG ABCC8
34 arteries, anomalies of 30.9 LEP INS ALB ADIPOQ
35 insulin-like growth factor i 30.9 SST LEP IRS1 INSR INS IGF1
36 diabetic encephalopathy 30.9 IRS1 INS IGF1
37 hyperuricemia 30.9 PPARG LEP INS ALB
38 lipoprotein quantitative trait locus 30.8 PPARG IRS1 INS GCG ALB ADIPOQ
39 polycystic ovary syndrome 30.8 PPARG LEP IRS1 INSR INS IGF1
40 microvascular complications of diabetes 1 30.8 SST INS IGF1 ALB
41 fatty liver disease 30.8 PPARG MALAT1 LEP IRS1 INSR INS
42 kidney disease 30.8 PPARG LEP INS GCG DPP4 ALB
43 maturity-onset diabetes of the young 30.8 SST PPARG PDX1 LEP KCNJ11 IRS1
44 macular retinal edema 30.8 INS ALB AKR1B1
45 sleep apnea 30.7 LEP INS IGF1 ALB ADIPOQ
46 bone resorption disease 30.7 PPARG LEP INS IGF1 ALB
47 proteasome-associated autoinflammatory syndrome 1 30.7 PPARG INS ALB ADIPOQ
48 fasting hypoglycemia 30.7 INSR IGF1
49 monogenic diabetes 30.7 PDX1 KCNJ11 INS HNF1A GCK ABCC8
50 hypothyroidism 30.6 SST LEP INS IGF1 ALB ADIPOQ

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia

Symptoms & Phenotypes for Hyperglycemia

UMLS symptoms related to Hyperglycemia:


seizures, fever, dyspnea, vertigo, cachexia, headache, syncope, cyanosis, edema, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.39 ABCC8 ADIPOQ AKR1B1 DPP4 GCK HNF1A
2 homeostasis/metabolism MP:0005376 10.39 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCK
3 endocrine/exocrine gland MP:0005379 10.32 ABCC8 ADIPOQ ALB DPP4 GCK HNF1A
4 cellular MP:0005384 10.29 ADIPOQ ALB DPP4 GCK HNF1A IGF1
5 adipose tissue MP:0005375 10.28 ADIPOQ HNF1A IGF1 INS INSR IRS1
6 cardiovascular system MP:0005385 10.26 ADIPOQ ALB DPP4 GCK IGF1 INS
7 immune system MP:0005387 10.22 ADIPOQ ALB DPP4 IAPP IGF1 INS
8 mortality/aging MP:0010768 10.2 ADIPOQ AKR1B1 ALB DPP4 GCK HNF1A
9 digestive/alimentary MP:0005381 10.1 ALB HNF1A INS INSR LEP PDX1
10 liver/biliary system MP:0005370 10.07 ADIPOQ ALB GCK HNF1A INS INSR
11 muscle MP:0005369 10 ADIPOQ ALB HNF1A IGF1 INS INSR
12 renal/urinary system MP:0005367 9.73 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
13 no phenotypic analysis MP:0003012 9.7 ABCC8 HNF1A INS KCNJ11 PDX1 PPARG
14 skeleton MP:0005390 9.4 ADIPOQ AKR1B1 HNF1A IAPP IGF1 INS

Drugs & Therapeutics for Hyperglycemia

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Saxagliptin Approved Phase 4 361442-04-8 11243969
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
tannic acid Approved Phase 4 1401-55-4
6
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
7
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
10
Glucagon Approved Phase 4 16941-32-5
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
13
Insulin detemir Approved Phase 4 169148-63-4 5311023
14
Insulin glulisine Approved Phase 4 207748-29-6
15
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
16
Glimepiride Approved Phase 4 93479-97-1 3476
17
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
18
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
19
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
20
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
21
Remifentanil Approved Phase 4 132875-61-7 60815
22
Ofloxacin Approved Phase 4 82419-36-1 4583
23
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
24
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
25
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
26
Losartan Approved Phase 4 114798-26-4 3961
27
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
28
Liraglutide Approved Phase 4 204656-20-2 44147092
29
Dulaglutide Approved, Investigational Phase 4 923950-08-7
30
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
31
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
32
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
33 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
34
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
35
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
36
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
37
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
38
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
39
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
40 Serotonin 5-HT1 Receptor Agonists Phase 4
41 Serotonin Receptor Agonists Phase 4
42 Dopamine agonists Phase 4
43 Omega 3 Fatty Acid Phase 4
44 Anti-Bacterial Agents Phase 4
45 HIV Protease Inhibitors Phase 4
46
protease inhibitors Phase 4
47 Colesevelam Hydrochloride Phase 4
48 Anticholesteremic Agents Phase 4
49 Dopamine Antagonists Phase 4
50 Dopamine Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 640)
# Name Status NCT ID Phase Drugs
1 Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Unknown status NCT03057470 Phase 4 50% bolus insulin correction;100% bolus insulin correction;150% bolus insulin correction
2 A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT) Unknown status NCT02802644 Phase 4 Sitagliptin;Non DPP-4 Inhibitor
3 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
4 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
5 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
6 ß-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia Unknown status NCT01717911 Phase 4 Insulin;Metformin;Sitagliptin
7 The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
8 A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
9 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
10 Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations Unknown status NCT03708887 Phase 4 Low dose omega-3 fatty acid supplementation;High dose omega-3 fatty acid supplementation;Control drug
11 A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia Completed NCT01239004 Phase 4 Placebo;Colesevelam
12 Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism Completed NCT00287820 Phase 4 Olanzapine;olanzapine;risperidone
13 A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents With Type 2 Diabetes Completed NCT02061969 Phase 4 linagliptin;insulin glargine
14 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
15 Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function Completed NCT00231894 Phase 4 Pioglitazone
16 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed NCT01810952 Phase 4 Glargine insulin;Lispro insulin;NPH Insulin
17 Randomized Controlled Study of Dipeptidyl Peptidase-4 (DPP4) Inhibitor (Sitagliptin) Therapy in the Inpatient Management of Patients With Type 2 Diabetes Completed NCT01378117 Phase 4 Sitagliptin;glargine;lispro
18 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
19 A Randomized, Controlled Trial of a Low-Carbohydrate, Ketogenic Diet Versus a Low-Glycemic Index Diet for Obesity-Related Type 2 Diabetes Completed NCT00415688 Phase 4
20 Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit Completed NCT00736229 Phase 4 Exenatide
21 Transitioning Post-cardiothoracic Surgery Patients From Intravenous Insulin to the Subcutaneous Route With Insulin Detemir. Completed NCT00717288 Phase 4 Detemir;Detemir;Detemir
22 Continuous Subcutaneous Infusion of Pramlintide and Insulin: A Randomized, Crossover Design Study Completed NCT00291772 Phase 4 Pramlintide
23 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery Completed NCT01545700 Phase 4 Control-saline;Dexamethasone 4 mg;Dexamethasone 8 mg;Control saline;Dexamethasone 4 mg;Dexamethasone 8 mg
24 Effect of Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) on Metabolic Syndrome Completed NCT01625442 Phase 4 Saffron tablet;Barberry tablet;Placebo
25 A Multi-center, Open-label, Randomized, Active-control, Parallel-group Designed Study to Compare Effects of Nateglinide and Acarbose on Postprandial Status in Chinese Drug-naive Type 2 Diabetes Mellitus Patients Completed NCT00928889 Phase 4 Nateglinide 120 mg;Acarbose 50 mg
26 Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD Completed NCT02253121 Phase 4 Dapagliflozin;Sliding scale insulin
27 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D) Completed NCT02973477 Phase 4 Dapagliflozin;Glimepiride
28 Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery Completed NCT02556918 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
29 Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery Completed NCT02443402 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
30 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
31 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
32 Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care Completed NCT00591227 Phase 4 insulins aspart and detemir
33 Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study Completed NCT02741687 Phase 4 Sitagliptin;Placebo;Supplemental insulin (insulin lispro);Supplemental insulin (insulin aspart);Long acting basal insulin (insulin detemir);Long acting basal insulin (insulin glargine)
34 The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro
35 Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
36 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
37 Reducing Postprandial Hyperglycemia With Adjuvant Premeal Pramlintide and Postmeal Insulin in Children With Type 1 Diabetes Mellitus. Completed NCT00442767 Phase 4 Insulin;Pramlintide + Insulin
38 Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
39 Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension Completed NCT00642434 Phase 4 carvedilol;metoprolol
40 Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen Completed NCT02408120 Phase 4 Insulin glargine;Insulin aspart;Supplemental insulin aspart
41 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
42 Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin Completed NCT00338104 Phase 4 insulin glargine;insulin glargine;insulin glargine
43 A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients. Completed NCT00220987 Phase 4
44 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation Completed NCT00779701 Phase 4 Insulin
45 Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit Completed NCT02165566 Phase 4 Regular-insulin;Lispro-insulin
46 Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study Completed NCT01409434 Phase 4 Oral Glucose Tolerance Test
47 Randomized Controlled Trial of Nurse-directed vs Nomogram-directed Intensive Glucose Control in the CVICU Completed NCT00636714 Phase 4
48 Effect of Different Enteral Nutrition Formulas on Glucose Homeostasis Completed NCT03012867 Phase 4
49 Basal Bolus Regimen With Insulin Analogs Versus Human Insulin in Medical Patients With Type 2 Diabetes: A Randomized Controlled Trial in Paraguay Completed NCT02278913 Phase 4 Basal Bolus (Glargine and Glulisine);Human Insulin
50 Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia in Diabetic and Non-Diabetic Patients. Completed NCT04456712 Phase 4 Ciprofloxacin 400 MG/200 ML Intravenous Solution;Levofloxacin 750 MG

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Insulin
insulin beef, isophane
insulin beef-pork, isophane
insulin degludec
Insulin Glargine
insulin human, isophane
Insulin Lispro
insulin pork, isophane
Insulin, Aspart Protamine, Human
Insulin, Aspart, Human
Insulin, Glulisine, Human
Insulin, Prompt Zinc, Beef
Insulin, Prompt Zinc, Beef-Pork
Insulin, Prompt Zinc, Pork
Insulin, Protamine Lispro, Human
insulin, protamine zinc, beef
Insulin, Protamine Zinc, Beef-Pork
Insulin, Protamine Zinc, Pork
Insulin, Regular, Beef
insulin, regular, beef-pork
Insulin, Regular, Pork
Insulin, Zinc, Human
Insulin, Zinc, Pork
INSULIN,DETEMIR,HUMAN
INSULIN,REGULAR,HUMAN BUFFERED
Lente Insulin, Beef
Lente Insulin, Beef-Pork
Regular Insulin, Human
Ultralente Insulin, Beef
Ultralente Insulin, Beef-Pork
Ultralente Insulin, Human

Cochrane evidence based reviews: hyperglycemia

Genetic Tests for Hyperglycemia

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 29

Anatomical Context for Hyperglycemia

MalaCards organs/tissues related to Hyperglycemia:

40
Endothelial, Kidney, Pancreas, Skeletal Muscle, Smooth Muscle, Bone Marrow, Pancreatic Islet

Publications for Hyperglycemia

Articles related to Hyperglycemia:

(show top 50) (show all 30507)
# Title Authors PMID Year
1
Caring for Hospitalized Patients with Diabetes Mellitus, Hyperglycemia, and COVID-19: Bridging the Remaining Knowledge Gaps. 42 61
33244614 2020
2
Effect of hyperglycemia on all-cause mortality from pediatric brain injury: A systematic review and meta-analysis. 42 61
33235087 2020
3
Myocardial glucotoxicity: Mechanisms and potential therapeutic targets. 42
33189592 2020
4
Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. 61 54
20184965 2010
5
C-reactive protein -717C>T genetic polymorphism associates with esophagectomy-induced stress hyperglycemia. 54 61
20145925 2010
6
Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. 61 54
20207740 2010
7
[Endothelial dysfunction in diabetes]. 61 54
20446576 2010
8
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. 54 61
20197503 2010
9
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. 61 54
20425568 2010
10
Hyperglycemia and hypoxia are interrelated in their teratogenic mechanism: studies on cultured rat embryos. 54 61
20127827 2010
11
The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. 54 61
20176725 2010
12
Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells. 54 61
20110858 2010
13
Addressing hyperglycemia from hospital admission to discharge. 54 61
20078323 2010
14
Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients. 54 61
19783893 2010
15
Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. 54 61
20124983 2010
16
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. 61 54
20448799 2010
17
Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. 61 54
19968982 2010
18
Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. 54 61
19757377 2010
19
Acute hyperglycemia produces transient improvement in glucose transporter type 1 deficiency. 54 61
20186957 2010
20
Naturally occurring glucokinase mutations are associated with defects in posttranslational S-nitrosylation. 61 54
19934346 2010
21
Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-kappaB pathway. 54 61
20495289 2010
22
"Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? 54 61
19643547 2009
23
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. 61 54
19945407 2009
24
High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. 54 61
19635557 2009
25
Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. 61 54
19564454 2009
26
Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. 61 54
19584310 2009
27
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. 54 61
19878567 2009
28
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus. 54 61
19309449 2009
29
Hyperinsulinemia predicts survival in a hyperglycemic mouse model of critical illness. 54 61
19623043 2009
30
Identification of a novel beta-cell glucokinase (GCK) promoter mutation (-71G>C) that modulates GCK gene expression through loss of allele-specific Sp1 binding causing mild fasting hyperglycemia in humans. 54 61
19411616 2009
31
Exposure of human keratinocytes to ischemia, hyperglycemia and their combination induces oxidative stress via the enzymes inducible nitric oxide synthase and xanthine oxidase. 54 61
19539448 2009
32
Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes. 54 61
19587243 2009
33
Hyperglycemia contributes to cardiac dysfunction in a lipopolysaccharide-induced systemic inflammation model. 54 61
19487929 2009
34
Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: interactions with adiponectin levels. 61 54
19429700 2009
35
Increased secretion of IP-10 from monocytes under hyperglycemia is via the TLR2 and TLR4 pathway. 54 61
19447045 2009
36
Hyperglycemia regulates RUNX2 activation and cellular wound healing through the aldose reductase polyol pathway. 61 54
19383984 2009
37
Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus. 61 54
19140902 2009
38
When oral agents fail: optimizing insulin therapy in the older adult. 54 61
19555131 2009
39
Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. 54 61
19336232 2009
40
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. 61 54
19276444 2009
41
[The relationship between serum level of leptin and oxidative stress in patients with hyperglycemia crisis]. 61 54
19570342 2009
42
Hyperglycemia and insulin therapy in the critically ill child. 54 61
19307807 2009
43
Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. 61 54
19450513 2009
44
Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia. 54 61
19190104 2009
45
The metabolic syndrome: insulin resistance. 54 61
19278606 2009
46
Endothelial heparanase secretion after acute hypoinsulinemia is regulated by glucose and fatty acid. 61 54
19218500 2009
47
Hyperglycemia acutely lowers the postprandial excursions of glucagon-like Peptide-1 and gastric inhibitory polypeptide in humans. 54 61
19174495 2009
48
The role of intensive insulin therapy in increasing superoxide dismutase (SOD) and normalizing hyperglycemia in critically ill patients. 54 61
19390123 2009
49
Dapagliflozin: an emerging treatment option in type 2 diabetes. 54 61
19243283 2009
50
The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. 54 61
19136606 2009

Variations for Hyperglycemia

ClinVar genetic disease variations for Hyperglycemia:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 KLF11 NM_003597.5(KLF11):c.23G>A (p.Gly8Asp) SNV Uncertain significance 523462 rs1553312826 2:10183866-10183866 2:10043739-10043739

Copy number variations for Hyperglycemia from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44162 10 52900000 70600000 Copy number TFAM Hyperglycemia

Expression for Hyperglycemia

Search GEO for disease gene expression data for Hyperglycemia.

Pathways for Hyperglycemia

Pathways related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 31)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 PPARG PDX1 LEP IRS1 INS IAPP
2
Show member pathways
13.23 PPARG LEP IRS1 INSR INS GCG
3
Show member pathways
12.85 PDX1 KCNJ11 INS GCK GCG ALB
4
Show member pathways
12.72 LEP IRS1 INSR INS ADIPOQ
5
Show member pathways
12.4 LEP IRS1 INS GCK
6
Show member pathways
12.37 PPARG LEP IRS1 INSR INS IGF1
7
Show member pathways
12.32 KCNJ11 INS GCG ADIPOQ ABCC8
8 12.3 SLC5A2 PPARG PDX1 IRS1 INSR INS
9
Show member pathways
12.26 PPARG IRS1 INSR IGF1
10
Show member pathways
12.21 LEP INS IGF1 GCG DPP4
11
Show member pathways
12.14 LEP IRS1 INSR INS
12
Show member pathways
12.06 PPARG IRS1 INSR INS IGF1 ADIPOQ
13
Show member pathways
12.03 IRS1 INSR INS IGF1
14 12.01 PDX1 INS IGF1 ALB
15
Show member pathways
11.99 PDX1 INSR INS HNF1A GCK
16 11.92 PPARG LEP IRS1 INS IGF1 HNF1A
17
Show member pathways
11.85 PDX1 INS IAPP HNF1A GCK
18 11.81 PPARG LEP INS IGF1 ADIPOQ
19 11.66 LEP IRS1 ADIPOQ
20 11.63 IRS1 INSR INS
21 11.55 IRS1 INSR INS
22
Show member pathways
11.54 LEP GCG DPP4
23 11.54 LEP KCNJ11 IRS1 ABCC8
24 11.51 LEP IRS1 INSR INS
25 11.49 INSR INS IGF1
26 11.41 IRS1 INSR INS
27 11.35 IRS1 INSR INS IGF1
28
Show member pathways
11.26 PDX1 KCNJ11 IRS1 INSR INS HNF1A
29 11.14 PPARG LEP ADIPOQ
30 11.14 PDX1 KCNJ11 INS HNF1A GCK ALB
31 11.06 PPARG LEP IRS1 INSR ADIPOQ

GO Terms for Hyperglycemia

Cellular components related to Hyperglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 SST LEP INS IGF1 IAPP GCG
2 extracellular space GO:0005615 9.81 SST LEP INS IGF1 IAPP GCG
3 inward rectifying potassium channel GO:0008282 8.96 KCNJ11 ABCC8
4 insulin receptor complex GO:0005899 8.62 IRS1 INSR

Biological processes related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.08 LEP IGF1 GCG ALB AKR1B1
2 positive regulation of cell proliferation GO:0008284 10 PDX1 LEP IRS1 INSR INS IGF1
3 carbohydrate metabolic process GO:0005975 9.96 SLC5A2 INSR INS GCK AKR1B1
4 cellular protein metabolic process GO:0044267 9.95 INS IGF1 IAPP ALB
5 response to drug GO:0042493 9.91 SST PPARG PDX1 KCNJ11 ADIPOQ ABCC8
6 positive regulation of protein kinase B signaling GO:0051897 9.88 LEP IRS1 INSR INS IAPP
7 insulin receptor signaling pathway GO:0008286 9.85 IRS1 INSR INS
8 cellular response to insulin stimulus GO:0032869 9.85 PPARG LEP IRS1 INSR GCK ADIPOQ
9 response to insulin GO:0032868 9.84 LEP IRS1 ABCC8
10 response to nutrient levels GO:0031667 9.84 PDX1 LEP ADIPOQ
11 response to glucose GO:0009749 9.83 PDX1 HNF1A ADIPOQ
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 LEP INSR INS IGF1
13 response to nutrient GO:0007584 9.81 SST PPARG LEP ADIPOQ
14 response to activity GO:0014823 9.8 LEP GCG ADIPOQ
15 positive regulation of MAPK cascade GO:0043410 9.8 LEP INSR INS IGF1 IAPP
16 placenta development GO:0001890 9.79 PPARG LEP HNF1A
17 activation of protein kinase B activity GO:0032148 9.78 INSR INS IGF1
18 positive regulation of DNA binding GO:0043388 9.77 PPARG PDX1 IGF1
19 negative regulation of insulin secretion GO:0046676 9.76 KCNJ11 IRS1 ABCC8
20 insulin secretion GO:0030073 9.75 PDX1 LEP HNF1A
21 positive regulation of mitotic nuclear division GO:0045840 9.74 INSR INS IGF1
22 regulation of insulin secretion GO:0050796 9.73 LEP KCNJ11 GCK GCG DPP4 ABCC8
23 positive regulation of insulin receptor signaling pathway GO:0046628 9.72 LEP IRS1 INS
24 positive regulation of glucose import GO:0046326 9.72 IRS1 INSR INS IGF1 ADIPOQ
25 positive regulation of glycolytic process GO:0045821 9.71 INSR INS IGF1
26 insulin-like growth factor receptor signaling pathway GO:0048009 9.68 IRS1 IGF1
27 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.68 PPARG ADIPOQ
28 positive regulation of protein kinase A signaling GO:0010739 9.67 IAPP ADIPOQ
29 negative regulation of gluconeogenesis GO:0045721 9.67 INS GCK ADIPOQ
30 neuron projection maintenance GO:1990535 9.66 INSR INS
31 cellular response to leptin stimulus GO:0044320 9.65 LEP GCK
32 negative regulation of acute inflammatory response GO:0002674 9.64 PPARG INS
33 positive regulation of respiratory burst GO:0060267 9.64 INSR INS
34 bone mineralization involved in bone maturation GO:0035630 9.63 LEP IGF1
35 glucose metabolic process GO:0006006 9.63 PDX1 LEP KCNJ11 INS GCK ADIPOQ
36 positive regulation of developmental growth GO:0048639 9.62 LEP INSR
37 positive regulation of fatty acid metabolic process GO:0045923 9.62 PPARG ADIPOQ
38 detection of glucose GO:0051594 9.6 PDX1 GCK
39 positive regulation of glycogen biosynthetic process GO:0045725 9.35 IRS1 INSR INS IGF1 GCK
40 glucose homeostasis GO:0042593 9.32 PPARG PDX1 LEP IRS1 INSR INS

Molecular functions related to Hyperglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 PPARG INSR INS IAPP HNF1A GCG
2 signaling receptor binding GO:0005102 9.77 LEP IAPP GCG DPP4 ADIPOQ
3 insulin receptor binding GO:0005158 9.33 IRS1 INS IGF1
4 ATP-activated inward rectifier potassium channel activity GO:0015272 9.32 KCNJ11 ABCC8
5 insulin-like growth factor receptor binding GO:0005159 9.26 IRS1 INSR INS IGF1
6 hormone activity GO:0005179 9.17 SST LEP INS IGF1 IAPP GCG

Sources for Hyperglycemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....